WEST LAFAYETTE, Ind.--(BUSINESS WIRE)-- Officials of Kylin Therapeutics Inc. announce that Dr. Henry Li will serve in the newly created position as director for the company's research and development team.
Dr. Li brings more than 13 years experience of biopharmaceutical research and development, as well as extensive expertise in academic research. He will be relocating from California to join Kylin Therapeutics.
"Indiana has experienced tremendous growth in the life sciences sector in the past few years and that has attracted top talent from both coasts," said Eric Davis, president and CEO of Kylin Therapeutics. "Bringing someone of Dr. Li's caliber to our team speaks both to the potential of Kylin’s pRNAi platform and the flourishing life sciences industry in Indiana."
Indiana is fourth in the nation for pharmaceutical research and development and ninth in the production and manufacturing in the biosciences, according to a recent study by the Battelle Memorial Institute in Columbus, Ohio.
Dr. Li began his career working at Immusol/iTherx Pharmaceuticals, a San Diego-based biotechnology company, for over 11 years, holding various R/D positions, including management positions of director of oncology and senior director of drug development.
Dr. Li has experience in gene silencing related technologies, including RNAi and ribozyme based platforms. He created the first randomized ribozyme library for gene inactivation. He also was the director of research and pharmacology at NexBio, a biopharmaceutical company focusing on novel biologic drug against pandemic influenza. At NexBio, Dr. Li was responsible for non-clinical development of Fludase, a clinical stage candidate, and other preclinical development.
Dr. Li was trained in molecular virology and cancer research, receiving his Ph.D. from University of California, Irvine, and postdoctoral training at UCLA School of Medicine. He has been a researcher with expertise in cancer and infectious diseases. He has authored more than 50 publications that include both peer reviewed research and book chapters. He has edited two drug development books and is currently on the editorial board of Journal Current Signal Transduction Therapy.
Kylin Therapeutics, Inc. (www.kylintherapeutics.com), a biotechnology company based in the Purdue Research Park, employs a revolutionary RNA nanoparticle technology platform called "pRNA" to exploit the enormous potential of oligonucleotides for treatment of many common diseases.
CONTACT:
Purdue Research Park
Cynthia Sequin, 765-588-3340
[email protected]
KEYWORDS: United States North America Indiana
INDUSTRY KEYWORDS: Technology Nanotechnology Health Biotechnology Infectious Diseases Oncology Pharmaceutical Other Health Research Science General Health
MEDIA:
| Logo |